Patents by Inventor Ralf Jager

Ralf Jager has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090005322
    Abstract: The present invention concerns a physiologically active composition which contains an enzymatically hydrolysed collagen as the active component I and at least one component of the non-vitamin type having anti-oxidative and/or anti-inflammatory properties as the active component II. Collagen of animal origin that is soluble in cold water comes into particular consideration as component I and a fermentation broth or a plant extract comes into particular consideration as component II. This composition which is designed in particular as a food supplement or functional food can be used to prevent inflammatory and/or degenerative symptoms in particular with a chronic course such as for example arthritis and arthroses or to successfully treat these symptoms. The claimed composition can be used above all by professional, leisure and recreational athletes who suffer in particular from strained joint functions.
    Type: Application
    Filed: July 27, 2005
    Publication date: January 1, 2009
    Inventors: Martin Purpura, Ralf Jager, Karim Balan, Dietrich Paper
  • Publication number: 20070009590
    Abstract: This physiologically active composition contains, as physiologically active constituents, the components a) phosphatidylserine and/or lysophosphatidylserine (in each case “PS”) and b) at least one (lyso)phospholipid different from component a) and c) a serine source different from component a), for example L-serine and/or O-phospho-L-serine. In this composition, the components a) and also b) and c) must each be present in a molar ratio a:b (where b<c) and a:c (where c<b) such that the components b) and c) can preferably form PS in vivo and in this manner ideally replace 10 to 99% by weight of the PS portion in the total formulation. The component a) should here make up 0.1 to 20% by weight of the total formulation and the components b) and c) should be present in portions between 15 and 65% by weight and in portions between 0.1 and 5.0% by weight, respectively.
    Type: Application
    Filed: September 3, 2004
    Publication date: January 11, 2007
    Inventors: Martin Purpura, Ralf Jager, Roland Rabeler, Hans-Ullrich Hoppe
  • Publication number: 20060280843
    Abstract: The present invention comprises a filler material for a container having at least one compartment, which container is situated in a pressurized beverage container and, immediately after the beverage container is opened, is suitable for mixing the filling into the drinks liquid surrounding the container. The filling itself is in granule form of defined particle diameter and is composed, in particular, of the main component a) in the form of a food supplement and an effervescent component b). The component a) which should be present in the filling in amounts of between 35 and 98% by weight can also be pharmaceutical active ingredients, vitamins, creatine derivatives, phospholipids, probiotics, minerals, unsaturated fatty acids and any desired mixtures thereof.
    Type: Application
    Filed: May 10, 2006
    Publication date: December 14, 2006
    Inventors: Ralf Jager, Martin Purpura, Reinhard Kroner
  • Publication number: 20060263486
    Abstract: The subject of the present invention relates to a filler material for a container having at least one chamber which is situated in a beverage container under pressure and immediately after the opening of the beverage container is suitable for the admixture of the filler material into the beverage liquid surrounding it. The filler material itself is in granule form and is composed of the chief component a) in the form of a nutritional supplement and an effervescent component b). The component a), which should be present in the filler material in percentages between 35 and 98 wt.-%, can be non-prescription agents, vitamins, creatine derivatives, phospholipids, probiotics, minerals, unsaturated fatty acids and any mixtures thereof. The fillers can be put into beverage liquids with varying pH, since due to their dissolving ability and due to the targeted selection of appropriate effervescence and bursting components can be dissolved quickly and completely in the beverage liquid.
    Type: Application
    Filed: May 18, 2005
    Publication date: November 23, 2006
    Inventors: Ralf Jager, Martin Purpura, Reinhard Kroner
  • Publication number: 20050220857
    Abstract: The invention concerns a physiologically compatible, phospholipid-containing, stable and hard matrix consisting of a supporting material and a bioactive component which has a total diameter of between 0.1 and 5000 ?m and contains ?5% by weight, based on the starting material, of acetone-insoluble components as the bioactive component, which are in particular phosphatidyl serine, phosphatidyl choline and such like, as well as lyso variants and/or derivatives thereof. This matrix which preferably has a supporting material consisting of carbohydrates and/or proteins and preferably additional bioactive substances as ingredients such as amino acids, vitamins, trace elements and similar substances, can have liquid contents and is used in particular in functional foods, special foods and dietary supplements.
    Type: Application
    Filed: April 17, 2003
    Publication date: October 6, 2005
    Inventors: Martin Purpura, Dirk Cremer, Ralf Jager, Michaela Thalhammer
  • Publication number: 20050175763
    Abstract: The claimed functional foods and specialized foods each contain a physiologically compatible phospholipid-containing stable matrix consisting of a supporting material and a bioactive component, the phospholipid component being in particular phosphatidyl serine, phosphatidyl choline and similar compounds, lyso variants and/or derivatives thereof. Liquid, solid and semiliquid forms of administration are preferred as the functional foods; food for tube feeding is regarded as preferred among the specialized foods. The matrix used for this should preferably have liquid contents and in particular have a diameter between 0.1 ?m and 5.0 mm. It is also preferred when the matrix develops a delayed release after its ingestion with the respective foods which should preferably take place in the gastro-intestinal tract.
    Type: Application
    Filed: April 17, 2003
    Publication date: August 11, 2005
    Inventors: Martin Purpura, Dirk Cremer, Ralf Jager, Michaela Thalhammer
  • Publication number: 20050096392
    Abstract: The invention relates to the use of creatine pyruvate for increasing stamina during highly intensive intermittent physical exertion. Said use is to be applied in particular during short-term intensive muscular exertion and/or muscular exertion of short-duration and/or that is repeated in short intervals, preferably during sprinting and sporting performances in running disciplines and during exercises using sports equipment provided with rollers, wheels or sliding surfaces, in addition to during raising, pulling and/or lifting movements of the extremities and the neck. The invention relates in particular to variants, in which muscular exertion is maintained for between 0.1 seconds and 5 minutes and/or during which the muscular exertion is carried out with a frequency of between 0.1 and 600 minutes. In the latter variant, the muscular exertion can increase with each interval.
    Type: Application
    Filed: April 3, 2003
    Publication date: May 5, 2005
    Inventors: Ralf Jager, Martin Purpura, Dirk Bokenkamp
  • Publication number: 20050037069
    Abstract: A description is given of formulations comprising solid and stable creatine/citric acid composition(s) and carbohydrate(s) or hydrates thereof having a weight ratio of the constituents creatine/citric acid composition(s) and carbohydrate(s) of 1:0.01 to 1.0. Carbohydrate components, which can be used in anhydrous form, as hydrates or as moist products, are in principle all polyhydroxyaldehydes and polyhydroxyketones. The creatine component is preferably used in anhydrous form or in aqueous alcoholic or organic solution. The formulations should preferably be prepared by reacting the carbohydrates in the form of solutions, suspensions or as solid substance with the creatine/citric acid composition or solution thereof at ?20 to 120° C. and, if appropriate, finally removing the liquid phase, or else by a thermal treatment, a treatment with ultrasound or microwave of mixtures consisting of the creatine component and solid carbohydrates, preferably in a vacuum.
    Type: Application
    Filed: November 29, 2002
    Publication date: February 17, 2005
    Inventors: Martin Purpura, Ivo Pischel, Ralf Jager, Gunter Ortenburger
  • Publication number: 20040234544
    Abstract: The invention concerns a formulation containing phosphatidylserine (PS) and/or lyso-phosphatidylserine for preventing and treating mental and physical stress states, where the phosphatidylserine is, among others, combined with plant extracts or essences. Daily doses of 50 to 1000 mg PS are envisaged within the scope of the present invention which are administered over a maximum period of six months. Preferred subjects are humans of 10 to 50 years of age.
    Type: Application
    Filed: February 6, 2004
    Publication date: November 25, 2004
    Inventors: Ralf Jager, Bokenkamp Dirk
  • Publication number: 20040235795
    Abstract: The invention concerns the use of phosphatidylserine (PS), lyso-phosphatidylserine or/and a physiologically acceptable salt thereof for the treatment of the attention deficit syndrome (ADHS) in small daily doses over a longer time period and in larger daily doses over a short period as well as in combination with suitable additives selected from the group comprising antioxidants, essential fatty acids, mineral substances, amino acids, mood-lifters or/and phospholipids. In this connection it is preferred to carry out the administration to probands aged 2 to 20 years preferably 3 to 10 years whereby the phosphatidylserine as well as the additives are used in solid and also in liquid formulations. Due to its positive properties phosphatidyl-serine is in particular suitable as a therapeutic agent or food supplement in connection with ADHS. The good tolerance of phosphatidylserine even in high doses and over a longer supplementation period and the excellent compliance should also be stressed.
    Type: Application
    Filed: June 24, 2004
    Publication date: November 25, 2004
    Inventors: Ralf Jager, Dirk Bokenkamp
  • Publication number: 20040077719
    Abstract: The invention relates to addition and/or co-ordination compounds consisting of creatine and citric acid in the ratio of >1.0 to 3.0:1.0. Said compounds are characterised in that they have (KBr) bands in the IR spectrum, where &ngr;=3425 (±5) cm−1 (s), 1624 (±5) cm−1 (m-s) and 1247 (±5) cm−1 (m). Said compounds, which preferably contain no organic solvent and are present in a solid, pulverulent form are produced in particular by a method, according to which, a1) creatine, containing a maximum content of 20 wt. % water, is reacted with citric acid or its salts at temperatures between 0 and 70° C., or a2) creatine and citric acid or its salts, containing a total water content of between 5 and 15 wt. %, are ground at temperatures between 0 and 70° C., or a3) creatine is reacted with citric acid or its salts, in the presence of a solvent at temperatures between 0 and 70° C. The corresponding solvent is then eliminated to a maximum residual content of 1.
    Type: Application
    Filed: October 31, 2003
    Publication date: April 22, 2004
    Inventors: Ralf Jager, Martin Purpura, Gunter Ortenburger
  • Publication number: 20040006139
    Abstract: The invention relates to choline pyruvate of formula (I) wherein 0<n≦10, and is a stabile, physiologically compatible formulation containing said choline pyruvate, water and/or an organic solvent such as glycerine, or is present in a solid and preferably a powder form. The invention also relates to a method for producing choline pyruvate, whereby choline hydroxide is placed in a solvent, such as water or a methanol/water mixture, at a temperature of between 0 and 98° C., then pyruvric acid is added drop by drop in external cooling conditions and mixed until a pH value of between 5.0 and 8.0 is reached, the solvent is then removed and finally the obtained product is added to a physiologically compatible solvent.
    Type: Application
    Filed: June 20, 2003
    Publication date: January 8, 2004
    Inventors: Ralf Jager, Martin Purpura, Gunter Ortenburger, Ivo Pischel
  • Publication number: 20030203854
    Abstract: A new composition for effecting serum cholesterol levels is claimed, said composition comprising a) at least a waxy acid with 23 to 50 carbon atoms or derivatives thereof and with serum cholesterol level reducing properties, and b) 0 to 99.99% by weight of at least a component with serum cholesterol level effecting properties, and c) 0 to 20% by weight of at least a pharmaceutically acceptable formulation aid. The efficacy of this composition can be enhanced by further incorporation of other cholesterol reducing agents, like lecithin, tocotrienol, saponins, fibers, long-chain waxy alcohols and niacin. The claimed composition combines the benefits of the single physiolocology active constituence together with the technology to increase the biovailability.
    Type: Application
    Filed: April 23, 2002
    Publication date: October 30, 2003
    Inventors: Ivo Pischel, Herbert Clinton Fairow, Ralf Jager
  • Patent number: 6503951
    Abstract: The invention relates to the use of creatine and/or creatine derivatives for treating typical disorders in women, for example PMS or dysmenorrhea, which involves the prophylactic of therapeutic use, in particular, of creatine monohydrate, creatine pyruvates, creatine ascorbates and creatine &agr;-ketoglutarates as creatine derivatives in preferred daily doses of 0.1 g to 20 g. The invention also provides for the use of creatine or its derivatives as mixtures with a pyruvate, ascorbate or &agr;-ketoglutarate. The creatine or its appropriate derivatives are not restricted to any particular form of application, which makes them all the more suitable for the many symptoms of typical female disorders.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: January 7, 2003
    Assignee: SKW Trostberg Aktiengesellschaft
    Inventors: Ivo Pischel, Helen Louise Holland, Brigitta Schwartz, Andrea Huber, Ralf Jäger
  • Publication number: 20020072541
    Abstract: The invention relates to the use of creatine and/or creatine derivatives for treating typical disorders in women, for example PMS or dysmenorrhea, which involves the prophylactic of therapeutic use, in particular, of creatine monohydrate, creatine pyruvates, creatine ascorbates and creatine &agr;-ketoglutarates as creatine derivatives in preferred daily doses of 0.1 g to 20 g. The invention also provides for the use of creatine or its derivatives as mixtures with a pyruvate, ascorbate or &agr;-ketoglutarate. The creatine or its appropriate derivatives are not restricted to any particular form of application, which makes them all the more suitable for the many symptoms of typical female disorders.
    Type: Application
    Filed: January 27, 2000
    Publication date: June 13, 2002
    Inventors: Ivo Pischel, Helen Louise Holland, Brigitta Schwartz, Andrea Huber, Ralf Jager